JPS5899412A - 感染性腎臓結石症治療剤 - Google Patents
感染性腎臓結石症治療剤Info
- Publication number
- JPS5899412A JPS5899412A JP57193259A JP19325982A JPS5899412A JP S5899412 A JPS5899412 A JP S5899412A JP 57193259 A JP57193259 A JP 57193259A JP 19325982 A JP19325982 A JP 19325982A JP S5899412 A JPS5899412 A JP S5899412A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- infectious
- nephrolithiasis
- pha
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010029148 Nephrolithiasis Diseases 0.000 title claims description 27
- 208000015181 infectious disease Diseases 0.000 title claims description 13
- 230000002458 infectious effect Effects 0.000 title claims description 11
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000000913 Kidney Calculi Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 239000004575 stone Substances 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 11
- 208000019206 urinary tract infection Diseases 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 108010046334 Urease Proteins 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 241000588770 Proteus mirabilis Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 231100000957 no side effect Toxicity 0.000 description 5
- 206010043275 Teratogenicity Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 231100000211 teratogenicity Toxicity 0.000 description 4
- 241000588748 Klebsiella Species 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 231100000299 mutagenicity Toxicity 0.000 description 3
- 230000007886 mutagenicity Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010011509 Crystalluria Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- -1 calcium anhydride Chemical class 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000003390 teratogenic effect Effects 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100480484 Rattus norvegicus Taar8a gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- JWSMTBMIGYJJJM-UHFFFAOYSA-N magnesium;azane Chemical compound N.[Mg+2] JWSMTBMIGYJJJM-UHFFFAOYSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT24897A/81 | 1981-11-05 | ||
| IT24897/81A IT1195288B (it) | 1981-11-05 | 1981-11-05 | Composizione farmaceutica per la terapia di calcolosi renale infetta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5899412A true JPS5899412A (ja) | 1983-06-13 |
| JPS6212766B2 JPS6212766B2 (enExample) | 1987-03-20 |
Family
ID=11215066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57193259A Granted JPS5899412A (ja) | 1981-11-05 | 1982-11-02 | 感染性腎臓結石症治療剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4499107A (enExample) |
| JP (1) | JPS5899412A (enExample) |
| AU (1) | AU539684B2 (enExample) |
| BE (1) | BE894864A (enExample) |
| CA (1) | CA1184500A (enExample) |
| CH (1) | CH652923A5 (enExample) |
| DE (1) | DE3240650A1 (enExample) |
| ES (1) | ES8404183A1 (enExample) |
| FR (1) | FR2515516B1 (enExample) |
| GB (1) | GB2110930B (enExample) |
| IT (1) | IT1195288B (enExample) |
| LU (1) | LU84453A1 (enExample) |
| NL (1) | NL8204138A (enExample) |
| NZ (1) | NZ202198A (enExample) |
| SE (1) | SE8206128L (enExample) |
| ZA (1) | ZA827674B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0543661U (ja) * | 1991-11-06 | 1993-06-11 | 三洋電機株式会社 | フアクシミリ装置 |
| JP2011512366A (ja) * | 2008-02-20 | 2011-04-21 | グノーシス・エツセ・ピー・アー | 葉酸塩、これらの組成物および使用 |
| CN104491516A (zh) * | 2014-11-28 | 2015-04-08 | 王志军 | 治疗肾结石的中药 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61126010A (ja) * | 1984-11-20 | 1986-06-13 | Lion Corp | 口腔用組成物 |
| DE3445253A1 (de) * | 1984-12-12 | 1986-06-26 | Dr. Madaus & Co, 5000 Köln | Nephrologisch-urologisches arzneimittel |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1288547A (enExample) * | 1970-02-06 | 1972-09-13 |
-
1981
- 1981-11-05 IT IT24897/81A patent/IT1195288B/it active
-
1982
- 1982-10-15 NZ NZ202198A patent/NZ202198A/en unknown
- 1982-10-16 CH CH6012/82A patent/CH652923A5/it not_active IP Right Cessation
- 1982-10-19 US US06/435,291 patent/US4499107A/en not_active Expired - Fee Related
- 1982-10-19 AU AU89469/82A patent/AU539684B2/en not_active Ceased
- 1982-10-20 ZA ZA827674A patent/ZA827674B/xx unknown
- 1982-10-25 CA CA000414081A patent/CA1184500A/en not_active Expired
- 1982-10-26 NL NL8204138A patent/NL8204138A/nl not_active Application Discontinuation
- 1982-10-28 GB GB08230869A patent/GB2110930B/en not_active Expired
- 1982-10-28 SE SE8206128A patent/SE8206128L/ unknown
- 1982-10-29 BE BE2/59894A patent/BE894864A/nl not_active IP Right Cessation
- 1982-11-02 JP JP57193259A patent/JPS5899412A/ja active Granted
- 1982-11-03 LU LU84453A patent/LU84453A1/fr unknown
- 1982-11-04 FR FR828218516A patent/FR2515516B1/fr not_active Expired - Fee Related
- 1982-11-04 ES ES517122A patent/ES8404183A1/es not_active Expired
- 1982-11-04 DE DE19823240650 patent/DE3240650A1/de active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0543661U (ja) * | 1991-11-06 | 1993-06-11 | 三洋電機株式会社 | フアクシミリ装置 |
| JP2011512366A (ja) * | 2008-02-20 | 2011-04-21 | グノーシス・エツセ・ピー・アー | 葉酸塩、これらの組成物および使用 |
| CN104491516A (zh) * | 2014-11-28 | 2015-04-08 | 王志军 | 治疗肾结石的中药 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2515516B1 (fr) | 1990-03-09 |
| GB2110930A (en) | 1983-06-29 |
| JPS6212766B2 (enExample) | 1987-03-20 |
| AU539684B2 (en) | 1984-10-11 |
| DE3240650C2 (enExample) | 1989-08-24 |
| NL8204138A (nl) | 1983-06-01 |
| ZA827674B (en) | 1983-08-31 |
| DE3240650A1 (de) | 1983-06-23 |
| SE8206128D0 (sv) | 1982-10-28 |
| AU8946982A (en) | 1983-05-12 |
| NZ202198A (en) | 1985-02-28 |
| IT1195288B (it) | 1988-10-12 |
| BE894864A (nl) | 1983-02-14 |
| CA1184500A (en) | 1985-03-26 |
| GB2110930B (en) | 1985-10-02 |
| SE8206128L (sv) | 1983-05-06 |
| FR2515516A1 (fr) | 1983-05-06 |
| ES517122A0 (es) | 1984-04-16 |
| US4499107A (en) | 1985-02-12 |
| LU84453A1 (fr) | 1983-06-13 |
| CH652923A5 (it) | 1985-12-13 |
| ES8404183A1 (es) | 1984-04-16 |
| IT8124897A0 (it) | 1981-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4626536A (en) | Compositions for combatting toxaemia | |
| WO1999029327A1 (en) | Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance | |
| US4814326A (en) | Pharmaceutical compositions based on diphosphonates for the treatment of arthrosis and osteoarthritis | |
| EP0424028A2 (en) | S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset hastened enhanced analgesics | |
| JPS5899412A (ja) | 感染性腎臓結石症治療剤 | |
| US3705946A (en) | Method of treating hyperuricemia | |
| JP6642892B2 (ja) | ジメチルアミノミケリオリドを含む肺線維化の治療薬 | |
| CN109999027B (zh) | 褪黑素的用途 | |
| JP4395368B2 (ja) | 細胞殺傷活性を有するカルシウム塩 | |
| Sams | Clinical pharmacology of cephalosporins in veterinary medicine | |
| AU651824B2 (en) | Pharmaceutical composition | |
| CN110974814A (zh) | 双硫仑在细菌感染疾病中的潜在应用 | |
| US4146644A (en) | Method and composition for treating urinary tract infections | |
| JP2005104982A (ja) | 中皮腫を治療する方法 | |
| RU2326656C2 (ru) | Способ лечения желудочно-кишечных болезней телят "левосульфацином" | |
| US4024256A (en) | Method and composition for treating urinary tract infections | |
| Rinkoff et al. | Toxic depression of the myeloid elements following therapy with the sulfonamides; report of 8 cases | |
| JPH03504506A (ja) | 蠕虫感染症の治療または予防用の医薬および動物薬組成物 | |
| RU2211035C1 (ru) | Противотуберкулезный препарат | |
| US4517309A (en) | Method for the treatment of calcifying pancreatitis | |
| JPH03193730A (ja) | 治療剤 | |
| Wein et al. | Oral methylene blue and the dissolution of renal calculi | |
| Glaser et al. | The diagnosis and treatment of bacterial endocarditis | |
| Lamm et al. | Medical therapy of experimental infection stones | |
| Prescott et al. | Effect of glycerine on toxicity of isoniazid in mice |